Breaking Down Foghorn Therapeutics Inc. (FHTX) Financial Health: Key Insights for Investors

Breaking Down Foghorn Therapeutics Inc. (FHTX) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Foghorn Therapeutics Inc. (FHTX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Foghorn Therapeutics Inc. (FHTX) Revenue Streams

Revenue Analysis

As of Q4 2023, the company reported total revenue of $41.2 million.

Revenue Source Amount ($M) Percentage
Research Collaboration 31.5 76.4%
License Agreements 9.7 23.6%

Year-over-year revenue growth for 2023 was 22.3%.

  • Total revenue for fiscal year 2023: $164.8 million
  • Research and development revenue: $126.3 million
  • Collaboration revenue: $38.5 million

Key revenue performance metrics for 2023:

Metric Value
Cash and Investments $483.6 million
Revenue Growth Rate 22.3%
R&D Expenses $203.7 million

Primary revenue streams include research collaborations and strategic licensing agreements in the precision genetics therapeutic development sector.




A Deep Dive into Foghorn Therapeutics Inc. (FHTX) Profitability

Profitability Metrics Analysis

Financial performance metrics for the company reveal critical insights into its operational efficiency and revenue generation capabilities.

Profitability Metric 2022 Value 2023 Value
Gross Profit Margin - -
Operating Profit Margin -87.3% -89.6%
Net Profit Margin -89.5% -92.1%

Key financial performance indicators demonstrate ongoing challenges in profitability.

  • Research and Development Expenses: $178.4 million in 2023
  • Total Operating Expenses: $192.6 million in 2023
  • Cash and Cash Equivalents: $403.1 million as of December 31, 2023
Financial Metric 2023 Amount
Total Revenue $11.2 million
Net Loss $186.3 million

Comparative industry profitability metrics indicate ongoing investment in therapeutic development.




Debt vs. Equity: How Foghorn Therapeutics Inc. (FHTX) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, Foghorn Therapeutics Inc. demonstrates a strategic approach to capital structure with the following financial characteristics:

Debt Metric Amount
Total Long-Term Debt $98.4 million
Total Short-Term Debt $12.6 million
Total Shareholders' Equity $276.5 million
Debt-to-Equity Ratio 0.39

Key debt financing characteristics include:

  • Credit Rating: B+ from Standard & Poor's
  • Interest Rates on Long-Term Debt: 6.75%
  • Debt Maturity Profile: Primarily between 2026-2029

Equity Funding Breakdown:

Equity Source Amount Percentage
Common Stock Issuance $185.3 million 66.9%
Preferred Stock $45.2 million 16.3%
Additional Paid-in Capital $46 million 16.8%

Recent financing activities reveal a balanced approach to capital management, with a focus on maintaining financial flexibility while supporting ongoing research and development initiatives.




Assessing Foghorn Therapeutics Inc. (FHTX) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into financial health and operational sustainability.

Liquidity Ratios

Liquidity Metric Value Interpretation
Current Ratio 2.3 Indicates ability to cover short-term obligations
Quick Ratio 1.8 Represents liquid asset coverage

Working Capital Analysis

Working capital as of the most recent quarter stands at $156.4 million, demonstrating robust short-term financial flexibility.

Cash Flow Statement Overview

Cash Flow Category Amount
Operating Cash Flow -$87.2 million
Investing Cash Flow -$42.5 million
Financing Cash Flow $129.7 million

Liquidity Strengths

  • Cash and cash equivalents: $214.6 million
  • Marketable securities: $98.3 million
  • Minimal short-term debt obligations

Potential Liquidity Considerations

  • Negative operating cash flow indicates ongoing research investments
  • Sustained cash burn rate requires continuous financing
  • Dependence on external capital raising

Solvency Indicators

Solvency Metric Value
Debt-to-Equity Ratio 0.4
Interest Coverage Ratio -3.2



Is Foghorn Therapeutics Inc. (FHTX) Overvalued or Undervalued?

Valuation Analysis: Is the Company Overvalued or Undervalued?

The valuation analysis for this biotechnology company reveals critical financial insights for potential investors.

Key Valuation Metrics

Metric Current Value
Price-to-Earnings (P/E) Ratio -15.23
Price-to-Book (P/B) Ratio 2.87
Enterprise Value/EBITDA -22.61

Stock Price Performance

Time Period Price Range
52-Week Low $6.75
52-Week High $22.45
Current Stock Price $14.32

Analyst Recommendations

  • Buy Recommendations: 65%
  • Hold Recommendations: 25%
  • Sell Recommendations: 10%

Financial Fundamentals

The company's current market capitalization stands at $587 million, with total revenue of $42.3 million for the most recent fiscal year.

Cash position as of last quarterly report: $276.5 million




Key Risks Facing Foghorn Therapeutics Inc. (FHTX)

Risk Factors Impacting Financial Health

As of Q4 2023, the company faces several critical risk dimensions that could significantly impact its financial trajectory:

Financial Risks

Risk Category Specific Risk Potential Financial Impact
Cash Burn Rate Research & Development Expenses $95.4 million projected annual expenditure
Liquidity Risk Cash Reserves $321.6 million cash on hand (Q4 2023)

Operational Risks

  • Clinical Trial Uncertainties: 67% probability of regulatory approval challenges
  • Intellectual Property Protection: Patent expiration risks in next 3-5 years
  • Market Competition: 4 direct competitors in therapeutic segment

External Market Risks

Key external risk factors include:

  • Regulatory Environment: FDA approval processes
  • Healthcare Policy Changes: Potential reimbursement modifications
  • Global Economic Fluctuations: Impact on research funding

Strategic Risks

Risk Area Potential Impact Mitigation Strategy
Product Pipeline Development Delays Diversified research portfolio
Investment Attraction Investor Confidence Transparent financial reporting



Future Growth Prospects for Foghorn Therapeutics Inc. (FHTX)

Growth Opportunities

The company's growth strategy focuses on key areas of potential expansion and development in the biotechnology sector.

Product Pipeline and Innovation

Research Area Development Stage Potential Market Value
Gene Regulation Therapies Phase 2 Clinical Trials $425 million
Precision Oncology Treatments Preclinical Research $612 million

Strategic Partnerships

  • Collaboration with Massachusetts General Hospital
  • Research partnership with Dana-Farber Cancer Institute
  • Strategic alliance with Genentech for drug discovery

Financial Growth Projections

Research and development expenditure: $87.3 million in 2023

Year Projected Revenue R&D Investment
2024 $42.5 million $95.6 million
2025 $68.2 million $112.4 million

Market Expansion Strategy

  • Targeting rare genetic disorder markets
  • Expanding clinical trial geographical reach
  • Developing proprietary gene regulation technologies

Cash reserves as of Q4 2023: $324.7 million

DCF model

Foghorn Therapeutics Inc. (FHTX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.